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From October 4 to November 2, 2001, the first 10 confirmed cases of inhalational
anthrax caused by intentional release of Bacillus anthracis were identified in the
United States. Epidemiologic investigation indicated that the outbreak, in the Dis-
trict of Columbia, Florida, New Jersey, and New York, resulted from intentional
delivery of B. anthracis spores through mailed letters or packages. We describe
the clinical presentation and course of these cases of bioterrorism-related inhala-
tional anthrax. The median age of patients was 56 years (range 43 to 73 years),
70% were male, and except for one, all were known or believed to have pro-
cessed, handled, or received letters containing B. anthracis spores. The median
incubation period from the time of exposure to onset of symptoms, when known
(n=6), was 4 days (range 4-6 days). Symptoms at initial presentation included
fever or chills (n=10), sweats (n=7), fatigue or malaise (n=10), minimal or nonpro-
ductive cough (n=9), dyspnea (n=8), and nausea or vomiting (n=9). The median
white blood cell count was 9.8 X 103 /mm3 (range 7.5 to 13.3), often with
increased neutrophils and band forms. Nine patients had elevated serum tran-
saminase levels, and six were hypoxic. All 10 patients had abnormal chest X-rays;
abnormalities included infiltrates (n=7), pleural effusion (n=8), and mediastinal
widening (seven patients). Computed tomography of the chest was performed on
eight patients, and mediastinal lymphadenopathy was present in seven. With mul-
tidrug antibiotic regimens and supportive care, survival of patients (60%) was
markedly higher (<15%) than previously reported.
Historically, human anthrax in its various forms has
been a disease of those with close contact to animals or ani-
mal products contaminated with  Bacillus anthracis spores.
In the mid-1800s, inhalational anthrax related to the textile
industry became known as woolsorters’ disease (in England)
(1) and ragpickers’ disease (in Germany and Austria)
because of the frequency of infection in mill workers exposed
to imported animal fibers contaminated with  B. anthracis
spores. In the early 1900s, human cases of inhalational
anthrax occurred in the United States in conjunction with
the textile and tanning industries. In the last part of the
20th century, with improved industrial hygiene practices
and restrictions on imported animal products, the number of
cases fell dramatically (1,2); however, death rates remained
high (>85%) (1,3). In 1979, in Sverdlovsk, former Soviet
Union, an apparent aerosol release of  B. anthracis spores
from a military facility resulted in the largest outbreak of
inhalational anthrax in the 20th century (3).
Before October 2001, the last case of inhalational
anthrax in the United States had occurred in 1976 (1,4).
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Identification of inhalational anthrax in a journalist in Flor-
ida on October 4, 2001, marked the beginning of the first
confirmed outbreak associated with intentional anthrax
release in the United States (5,6). We describe the clinical
presentation of the first 10 cases of this bioterrorism-related
outbreak.
Methods
From October 4 to November 2, 2001, the Centers for
Disease Control and Prevention (CDC) and state and local
public health authorities reported 10 confirmed cases of
inhalational anthrax and 12 confirmed or suspected cases of
cutaneous anthrax in persons who worked in the District of
Columbia, Florida, New Jersey, and New York (6,7). Epide-
miologic investigation indicated that the outbreak resulted
from intentional delivery of  B. anthracis spores through
mailed letters or packages.
Of the 10 inhalational cases, 7 occurred in postal
employees in New Jersey and the District of Columbia who
were likely exposed to letters known to be contaminated
with B. anthracis spores. Two cases were in employees of a
media company in Florida: one is believed to have received
contaminated mail, the other to have sorted and distributed
that mail. Case 10 was in a resident of New York, and the
nature of her exposure to B. anthracis is currently unknown.
In the course of the US Public Health Service response
to the outbreak, CDC, in conjunction with state and local
health departments, collected clinical data from patients
with confirmed inhalational anthrax as defined by the CDC
surveillance case definition (8). Data were collected through
a variety of methods, including interviews with patients and
family members, physical examinations of patients, discus-
sions with clinicians, reviews of medical records, and analy-
ses of clinical and pathologic specimens.
Presumptive isolation of B. anthracis in these patients
was confirmed by gamma phage lysis, presence of a capsule,
detection of capsule and cell-wall antigens by direct fluores-
cent antibody, and  B. anthracis-specific polymerase chain
reaction (PCR). All isolates were confirmed by state and
other laboratory facilities of the National Bioterrorism Labo-
ratory Response Network and by the laboratories of the
National Center for Infectious Diseases (NCID), CDC. Other
tests performed at NCID for confirming the diagnosis of
inhalational anthrax (8) included immunohistochemical test-
ing of clinical specimens by using B. anthracis capsule and
cell-wall antibody, B. anthracis-specific PCR, and serologic
detection of immunoglobulin (Ig) G to B. anthracis protective
antigen (PA).
Case Descriptions
Case 1
On October 2, 2001, a 63-year-old Caucasian photo edi-
tor working for a Florida newspaper awoke early with nau-
sea, vomiting, and confusion and was taken to a local
emergency room for evaluation. His illness, which started on
September 27 during a trip to North Carolina, was charac-
terized by malaise, fatigue, fever, chills, anorexia, and
sweats. No history of headache, cough, chest pain, myalgias,
dyspnea, abdominal pain, diarrhea, or skin lesions was
reported. Past medical history included hypertension, cardio-
vascular disease, and gout. He did not smoke. On admission,
the patient was alert and interactive but spoke nonsensi-
cally. Temperature was 39.2oC, heart rate 109/min; blood
pressure and respiratory rate were normal. Initial pulmo-
nary, heart, and abdominal examinations were reported as
normal. No nuchal rigidity was observed. He was not ori-
ented to person, place, or time. Admission laboratory values
included a normal total white blood cell (WBC) count, but
the platelet count was low. Serum chemistries were normal,
except for borderline hyponatremia and elevated total biliru-
bin. He had mild metabolic acidosis (Table 1). A chest X-ray
showed a prominent superior mediastinum and a possible
small left pleural effusion (Figure 1). Cerebrospinal fluid
(CSF) analysis showed WBC count 4,750/mL (81% neutro-
phils), red blood cell count 1,375/mL, glucose 57 mg/dL
(serum glucose 174 mg/dL), and protein 666 mg/dL. Micros-
copy examination of the CSF showed many gram-positive
bacilli (Figure 2). B. anthracis was isolated from CSF after 7
hours of incubation and from blood cultures within 24 hours
of incubation. The patient was admitted to the hospital with
a diagnosis of meningitis. After a single dose of cefotaxime,
he was started on multiple antibiotics, including ceftazidime,
gentamicin, metronidazole, doxycycline, ampicillin, and tri-
methoprim-sulfamethoxazole. Shortly after admission, he
had generalized seizures and was intubated for airway pro-
tection. On hospital day 2, penicillin G, levofloxacin, and
clindamycin were begun; ampicillin, ceftazidime, and trime-
thoprim-sulfamethoxazole were discontinued. He remained
febrile and became unresponsive to deep stimuli. His condi-
tion progressively deteriorated, with hypotension and wors-
ening renal insufficiency. The patient died on October 5.
Autopsy findings included hemorrhagic mediastinal lym-
phadenitis, and immunohistochemical staining showed dis-
seminated B. anthracis in multiple organs.
Case 2
On September 24, a 73-year-old Hispanic man, the
newspaper mailroom clerk who delivered mail to the patient
in Case 1, had onset of fatigue. On September 28, nonproduc-
tive cough, intermittent fever, rhinorrhea, and conjunctivitis
developed. From September 28 to October 1, he had gradual
progression of cough, marked worsening of fatigue with leth-
argy, onset of exertional dyspnea, fever, and sweats. He had
mild abdominal pain associated with vomiting, and his co-
workers and family noted intermittent periods of confusion.
He had no underlying chronic illnesses, with the exception of
a transient ischemic attack in August 2001. He did not
smoke. He was admitted to the hospital on October 1. Tem-
perature was 38.5oC, heart rate 109/min, respiratory rate 20/
min, and blood pressure 108/61 mm Hg. He had bilateral
conjunctival injection and bilateral pulmonary rhonchi.
Examination, including assessment of neurologic function,
was otherwise unremarkable. No skin lesions were observed.
Admission laboratory results included normal WBC count
and serum chemistries, except for hypoalbuminemia, ele-
vated hepatic transaminases, borderline hyponatremia, and
increased creatinine. Arterial blood gas values showed
hypoxia (Table 1). Blood cultures obtained on hospital day 2,
after initiation of antibiotics, showed no growth. A chest X-
ray showed left upper and lower lobe infiltrates consistent
with pneumonia and a small left pleural effusion (Figure 3).Research
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No mediastinal widening was observed. The patient was
initially given intravenous azithromycin; cefotaxime and
ciprofloxacin were subsequently added. A nasal swab
obtained on October 5 grew B. anthracis. Computed tomog-
raphy (CT) of the chest showed bilateral effusions and multi-
lobar pulmonary consolidation but no significant
mediastinal lymphadenopathy (Figure 4). A left thoracente-
sis yielded serosanguinous fluid (Table 1) positive for  B.
anthracis DNA by PCR. Bronchoscopy showed bloody secre-
tions in the right lower lobe and left lung, with severe
mucosal hyperemia, mottling, and inflammation. Bacterial
cultures of bronchial washings and pleural fluid did not
grow. A transbronchial biopsy showed B. anthracis capsule
and cell-wall antigens by immunohistochemical staining.
Tests for  Legionella spp., acid-fast bacteria, Pneumocystis
carinii, Chlamydia spp.,  Leptospira, and  Hantavirus and
other viral pathogens were negative. The hospital course
included an episode of supraventricular tachycardia with
hypotension, maximum WBC count 26,800/ mm3, and recur-
rent left pleural effusion that required repeat thoracentesis
and placement of a chest tube. The pleural fluid from the sec-
ond thoracentesis was positive for B. anthracis DNA by PCR.
A pleural fluid cytology preparation and pleural biopsy
showed B. anthracis capsule and cell-wall antigens by immu-
Table 1. Laboratory findings at initial visit to health-care provider for 10 patients with bioterrorism-related inhalational anthrax, October  through
November 2001
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9a Case 10
WBC/mm3b 9,400 9,900 7,500 9,700 10,300 13,300 9,700 8,100 11,200 11,400
WBC differential
  Neutrophils %
  Band forms %
  Lymphocytes%
  Monocytes%
76
ND
15
9
72
ND
10
17
76
8
7
7
43
10
24
15
83
4
6
7
78
ND
11
8
79
ND
14
7
50
6
30
10
67
14
8
11
83
ND
9
7
Hematocrit % 45.7 47.1 46.9 48.6 43.0 51.4 44.7 45.3 42.5 46.3
Platelet count x 103/
mm3
109 WNL WNL WNL WNL WNL WNL WNL WNL WNL
Sodium mmol/l 132 WNL WNL WNL ND WNL 134 133 133 134
Potassium mmol/l WNL WNL WNL WNL ND WNL 3.4 WNL WNL WNL
Chloride mmol/l WNL WNL WNL WNL ND WNL WNL 98 WNL WNL
Bicarbonate mmol/L WNL WNL WNL WNL ND WNL 20 WNL WNL WNL
Creatinine mg/dL WNL 1.2 WNL WNL ND WNL WNL WNL WNL WNL
SGOT IU/L WNL 405 106 153 ND WNL ND 269 130 240
SGPT IU/L WNL 408 123 184 ND 44 ND 168 120 263
Alkaline 
phosphatase IU/L
WNL 141 165 171 ND WNL ND WNL 147 WNL
Albumin g/dL WNL 2.3 2.9 2.9 ND WNL ND WNL 3.4 3.3
Bilirubin mg/dL 1.5 WNL 1.9 1.7 ND WNL ND WNL WNL WNL
Arterial pH 7.32 7.48 7.45 7.46 ND ND ND 7.51 ND 7.41
Arterial PaCO2 mm Hg 37 33 27 38 ND ND ND 26 ND 40
Arterial PaO2 mm Hg 
(FiO2)
208
(70%)
52
(RA)
80
(RA)
66
(RA)
ND ND ND 58
(RA)
ND 122
(100% 
NRBR)
Pleural fluid
  RBC/mm3
ND 110,000 243,586 179,841 ND ND ND 80,000 “Many” 73,000
  WBC/mm3
  (% neutrophils)
ND 2,260 
(58%)
1,707 
(15)
1,633 
(6)
ND ND ND 785 (12) 286 (71) 3,000 
(90)
 Protein g/dL ND 2.6 2.7 4.3 ND ND 2.01 4.8 4.1 4.2
  LDH IU/L ND 282 1,762 965 ND ND 261 319 740 1,264
a The patient in Case 9 was initially seen as an outpatient 2 days before hospital admission, but had no laboratory studies performed at that time. These results
were obtained from studies done on the day of admission.
b WBC = white blood cells; WNL = within normal limits; ND = not done; NA = not available; SGOT = serum glutamic oxalacetic transaminase; SGPT = serum
glutamic pyruvic transaminase; FiO 2 = fraction of inspired O2; RA = room air; NRBR = nonrebreather mask; RBC = red blood cells; LDH = lactate
dehydrogenase Research
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nohistochemical staining. In addition, serial serum samples
demonstrated a >4-fold rise in levels of serum antibody (IgG)
to the PA component of the anthrax toxins by enzyme-linked
immunosorbent assay (ELISA). The patient’s condition grad-
ually improved, and he was discharged from the hospital
October 23 on oral ciprofloxacin.
Case 3
On October 16, a 56-year-old African-American man, a
US Postal Service mail sorter, noted low-grade fever, chills,
sore throat, headache, and malaise. This was followed by
minimal dry cough, chest heaviness, shortness of breath,
night sweats, nausea, and vomiting. On October 19, when he
arrived at a local hospital, he was afebrile and normotensive.
Heart rate was 110/min, and he was not tachypneic. He was
in no acute distress but had decreased breath sounds and
rhonchi at the left base. No skin lesions were observed. His
past medical history was unremarkable, and he did not
smoke. Total WBC count was normal, but there was a slight
left shift in the differential. Hepatic transaminase levels and
bilirubin were elevated. Serum albumin was decreased, but
serum chemistries and renal function were normal. Arterial
blood gas values showed adequate oxygenation (Table 1). A
chest X-ray showed a widened mediastinum (especially in
the right paratracheal region), bilateral hilar masses, bilat-
eral pleural effusions, and a small right lower lobe air space
opacity. CT of the chest showed diffuse mediastinal edema;
marked paratracheal, subcarinal, hilar, and azygo-esoph-
ageal recess adenopathy (the largest node measuring 4.2 cm
in diameter); and bilateral moderate pleural effusions.
Within 11 hours, admission blood cultures grew B. anthracis.
Ciprofloxacin, rifampin, and clindamycin were initiated. On
October 21, the patient had respiratory distress, which was
treated with diuretics, systemic corticosteroids, and a thera-
peutic thoracentesis. During the course of hospitalization,
the pleural effusion reaccumulated, necessitating two addi-
tional thoracenteses. All three pleural fluid specimens were
hemorrhagic. The patient did not require a chest tube.
Hematemesis developed, and several shallow gastric ulcers
were noted on upper endoscopy. On October 28, the patient
had signs of hemolytic anemia and thrombocytopenia, which
was treated with plasmapheresis. Hematologic values subse-
quently improved, and the patient remains hospitalized in
stable condition.
Case 4
On October 16, a 56-year-old African-American man, a
US Postal Service worker, noted mild headache that was con-
stant and global but not associated with visual changes, stiff
neck, or other neurologic symptoms. Over the following 3
days, the headache worsened and was accompanied by low-
grade fever, chills, sore throat, myalgias, nausea, malaise,
Figure 1. Initial chest X-ray (Case 1) showing prominent superior
mediastinum and possible small left pleural effusion.
Figure 2. Gram stain of cerebrospinal fluid (Case 1) showing B.
anthracis.
Figure 3. Chest X-ray (Case 2) showing diffuse consolidation consis-
tent with pneumonia throughout the left lung. There is no evidence
of mediastinal widening.Research
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drenching sweats, intermittent blurred vision, and photo-
phobia. A mild dry cough, dyspnea on exertion, and pleuritic
chest pain developed. When he arrived at the hospital on
October 20, he was afebrile and normotensive, pulse was
127/min, and respiratory rate 20/min. He was in no acute
distress, and physical examination was unremarkable,
except for decreased breath sounds at both bases. His past
medical history was unremarkable, and he did not smoke.
Admission laboratory results were normal, except for ele-
vated bilirubin and hepatic enzymes, low albumin, and
hypoxia (Table 1). A noncontrasted head CT was normal, and
CSF exhibited 4 WBC/mL (all lymphocytes), 20 RBC/mL, with
normal glucose and protein. No organisms were seen on
Gram stain of the CSF, and CSF culture did not grow. An
anteroposterior chest X-ray showed a widened mediastinum,
bilateral hilar masses, right pleural effusion, and bilateral
perihilar air space disease. A noncontrasted chest CT scan
showed diffuse mediastinal edema; bilateral pleural effu-
sions; bibasilar air space disease; and marked paratracheal,
subcarinal, hilar, and azygo-esophageal recess adenopathy.
Admission blood cultures grew B. anthracis within 15 hours.
Ciprofloxacin, rifampin, and clindamycin were begun. On
October 22, signs of worsening respiratory distress devel-
oped, and on October 23, the patient underwent therapeutic
thoracentesis, which yielded bloody pleural fluid, after which
his condition improved. He also received systemic cortico-
steroids for bronchospasm. He required a second thoracente-
sis and was discharged from the hospital on November 9.
Case 5
On October 16, a 55-year-old African-American man, a
District of Columbia US Postal Service employee, became ill.
He had fever, intermittent diaphoresis, myalgias, and cough
productive of green sputum but no shortness of breath, chest
discomfort, gastrointestinal symptoms, or headache. When
he visited his primary-care provider on October 18, he had
temperature of 38.9oC, normal heart rate and blood pres-
sure, and respiratory rate of 24/min. He had no other notable
examination findings, but WBC count was slightly elevated
(Table 1). His past medical history included diabetes melli-
tus and sarcoidosis. He did not smoke. No chest X-ray was
performed. He was sent home with a diagnosis of a viral syn-
drome; no antibiotics were prescribed. On October 21, he
arrived at the emergency department with worsening symp-
toms, including chest tightness, fatigue, chills, myalgias,
nausea, vomiting, and shortness of breath. Temperature was
38.9oC, pulse 93 to 150/min and irregular, respiratory rate
20/min, and blood pressure 119/73 mm Hg. Signs of respira-
tory distress were observed. Examination findings included
rales at the right base with diffuse wheezing and tachycar-
dia. WBC count was 18,800/mm3 with a differential of 73%
segmented neutrophils, 6% bands, 11% lymphocytes, and 8%
monocytes. Hematocrit was 55%, and platelets were 141,000/
mm3. Sodium was 130 mmol/L, potassium 5.3 mmol/L, chlo-
ride 99 mmol/L, and bicarbonate 14 mmol/L, with an anion
gap of 17. Creatinine was 1.6 mg/dL, and glucose was 425
mg/dL. Aspartate aminotransferase (AST) was 76 IU/L and
alanine aminotransferase (ALT) was 77 IU/L. Coagulation
studies were normal. Arterial pH was 7.42, PaCO2 25 mm
Hg, PaO2 66 mm Hg, and O2 saturation 93% on 2 L of O2/min
by nasal cannula. A chest X-ray showed right hilar and peri-
tracheal soft tissue fullness with right middle and lower lobe
infiltrates compatible with pneumonia and right pleural
effusion. An electrocardiogram showed atrial fibrillation.
The patient was intubated, ventilated, and administered
levofloxacin, diltiazem, and insulin. Later on the day of
admission, the patient became hemodynamically unstable,
had cardiac arrest, and died. Blood cultures grew B. anthra-
cis. Autopsy findings included hemorrhagic mediastinal lym-
phadenitis, and immunohistochemical staining showed
evidence of disseminated B. anthracis.
Case 6
On October 16, a 47-year-old African-American man, a
US Postal Service employee who worked at the same District
of Columbia mail distribution center associated with cases 3,
4, and 5, had mild nonproductive cough, nausea, vomiting,
and stomach cramps. On October 20, the patient had a syn-
copal episode at church but did not seek medical attention.
Early in the morning of October 21, he arrived at an emer-
gency department complaining of vomiting and profuse
sweating. His past medical history included asthma and
renal calculi. Therapy for asthma had not recently included
corticosteroids. He was afebrile and had orthostatic hypoten-
sion. WBC count was slightly elevated, but he had normal
serum chemistries and coagulation values. Serum glutamic
pyruvic transaminase (SGPT) was slightly elevated (Table
1). A chest X-ray was initially read as normal, but later
review noted an ill-defined area of increased density due to
infiltrate or mass in the right suprahilar region. The patient
was discharged after receiving intravenous hydration. On
the morning of October 22, he visited the emergency depart-
ment again, reporting myalgias, chills, dyspnea, continued
vomiting, and another syncopal episode. His temperature
was 35.6°C, blood pressure 76/48 mm Hg, heart rate 152/
min, and respiratory rate 32/min. He was ill-appearing with
mottled skin that was cool to the touch, and he was in respi-
Figure 4. Computed tomography of chest (Case 2) showing bilateral
pulmonary consolidation and pleural effusions.Research
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ratory distress. He had bilateral wheezing, tachycardia, and
mildly distended abdomen with absent bowel sounds. WBC
count was 31,200/mm3 with a differential of 78% segmented
neutrophils, 2% bands, 14% lymphocytes and 3% monocytes.
Sodium was 148 mmol/L, bicarbonate 18 mmol/L, anion gap
21, and creatinine 2.8 mg/dL. Serum glutamic oxalacetic
transaminase (SGOT) was 47 IU/L, SGPT 33 IU/L, and alka-
line phosphatase 197 IU/L. Prothrombin time was 13.3 sec-
onds and partial thromboplastin time was 40 seconds.
Penicillin, ceftriaxone, rifampin, and levofloxacin were
begun. Respiratory distress developed, which required
endotracheal intubation and mechanical ventilation. Soon
thereafter signs consistent with peritonitis were observed.
Arterial pH was 7.13, PaCO2 37 mm Hg, PaO2 106 mm Hg,
and oxygen saturation 95% after intubation on 100% FiO2. A
chest X-ray showed bilateral lung infiltrates concentrated
within perihilar and infrahilar regions without pleural effu-
sions. Chest and abdominal CT scans with intravenous con-
trast noted large bilateral pleural effusions, perihilar and
suprahilar infiltrates, mediastinal edema, pneumomediasti-
num, ascites, air in the portal venous system, mesenteric
edema, diffuse small bowel edema, and small collections of
intramural air involving several parts of the jejunum. CT of
the head was normal. The patient died within 6 hours of
admission. Gram-positive bacilli were visible on the buffy
coat blood smear, and blood cultures grew  B. anthracis
within 18 hours. Postmortem findings included prominent
hemorrhagic mediastinal lymphadenitis and evidence of sys-
temic B. anthracis infection by histopathologic and immuno-
histochemical tests. 
Case 7
On the evening of October 22, a 59-year-old Caucasian
man, contract employee at a U.S. State Department mail
sorting facility that received mail from the District of Colum-
bia postal facility associated with cases 3, 4, 5, and 6, became
ill. He had drenching sweats, followed over the next 2 days
by fatigue, severe myalgias, subjective fever, chills, head-
ache, nausea, vomiting, abdominal pain, cough with scant
white sputum, and substernal chest pain. He had no dysp-
nea or diarrhea. When he arrived at a local emergency room
on October 24, temperature was 38.2°C, heart rate 116/min,
and respiratory rate and blood pressure were normal. A com-
plete blood count was normal, and serum electrolytes showed
hyponatremia and hypokalemia (Table 1). His past medical
history was unremarkable, and he did not smoke. A chest X-
ray was initially reported as normal. The patient was
thought to have a viral syndrome and was discharged, but
blood cultures were obtained and ciprofloxacin was pre-
scribed. He took one dose that night, but vomiting, fatigue,
and headache worsened. He also reported transient distor-
tion in his left visual field, and his wife reported that he was
intermittently confused. Blood cultures grew gram-positive
bacilli after 17 hours of incubation; therefore, on October 25,
he was called back to the hospital for admission. The blood
isolate was subsequently identified as  B. anthracis. At
admission, his vital signs were as follows: temperature
38.2oC, heart rate 108/min, respiratory rate 20/min, blood
pressure 121/60 mm Hg, and oxygen saturation 94% on room
air. He appeared ill and had decreased breath sounds at the
right base. The rest of the examination was unremarkable.
Laboratory studies on admission included WBC count 9,500/
mm3 with 81% segmented neutrophils, 9% lymphocytes, and
9% monocytes, hematocrit 48.1%, platelet count 196,000/
mm3, normal electrolytes and creatinine, SGOT 85 IU/L,
SGPT 64 IU/L, alkaline phosphatase 141 IU/L, bilirubin 1.6
mg/dL, and albumin 3.0 mg/dL. On review, the initial chest
X-ray showed mediastinal widening (Figure 5), and chest CT
on the day of admission showed mediastinal adenopathy
with evidence of hemorrhage, normal lung parenchyma,
small bilateral pleural effusions, and a suspected small peri-
cardial effusion (Figure 6). Intravenous penicillin and
rifampin were added to the ciprofloxacin. His temperature
rose to 39o C. Subsquently, vancomycin was added and peni-
cillin was discontinued. On October 26, gastrointestinal
bleeding developed, which required blood transfusion, endo-
scopic injection, and cautery of gastric and duodenal ulcers.
On October 27, atrial fibrillation with variable ventricular
response developed. On October 28, fever reached a maxi-
mum of 39.4oC and then decreased to 38.3o C. On October 30,
WBC peaked at 31,300/mm3. On October 31, enlargement of
Figure 5. Chest X-ray (Case 7) showing mediastinal widening and a
small left pleural effusion.
Figure 6. Computed tomography of chest (Case 7) showing mediasti-
nal adenopathy and small bilateral pleural effusions.Research
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the right pleural effusion required thoracentesis and
removal of 900 cc of serosanguinous fluid (Table 1). The
patient was discharged from the hospital on November 9.
Case 8
On October 14, a 56-year-old African-American woman
who worked as a mail sorter in the Hamilton, New Jersey,
US Postal Service facility, became ill with vomiting and diar-
rhea, followed the next day by subjective fever and chills
unrelieved by aspirin. The vomiting and diarrhea improved,
but over the next 2 days she had fevers to 38.4 oC with shak-
ing chills, headache, and fatigue. A nonproductive cough
developed, along with mild shortness of breath, and anterior
chest pain on inspiration. She had no sore throat or rhinor-
rhea. On October 19, because of persistent fever and worsen-
ing chest pain, she went to a local emergency room. Findings
at that time included temperature 38.4oC, heart rate 120/
min, blood pressure 159/95 mm Hg, and respiratory rate 18/
min. She appeared ill with increased respiratory effort, had
decreased breath sounds at both bases, and had a 0.5- to 1.0-
cm healing scab on the anterior neck. Initial WBC was nor-
mal except for elevation in neutrophil band forms, and
hematocrit and platelets were normal. Serum electrolytes,
creatinine, and coagulation values were unremarkable,
except for hyponatremia. Hepatic enzymes were elevated,
and she was hypoxic (Table 1). Her past medical history
included a transient ischemic attack. She did not smoke. A
chest X-ray showed bibasilar infiltrates and a small right
pleural effusion but no mediastinal widening. Initial differ-
ential diagnosis included atypical pneumonia versus inhala-
tional anthrax, and the patient was begun on levofloxacin;
rifampin was added the next day. Two days later, the fever
persisted, dyspnea worsened, and large bilateral pleural
effusions developed. Antibiotics were changed to ciprofloxa-
cin, rifampin, and vancomycin. Right-sided thoracenteses
were performed on October 21 and 22, and 750 cc and 650 cc
of hemorrhagic fluid were removed, respectively. On October
23, a right chest tube was placed. A chest CT on October 22
showed mediastinal and cervical lymphadenopathy, bibasilar
infiltrates, and large left pleural effusion. On October 25, the
enlarging left-sided effusion required chest tube placement.
On October 26, the fever resolved, transaminases became
normal, and the dyspnea gradually improved. On October 30
and November 1, the chest tubes were removed. On Novem-
ber 5, the patient was discharged from the hospital. Blood for
B. anthracis DNA by PCR was positive, as were immunohis-
tochemistry studies for  B. anthracis cell-wall and capsule
antigens from pleural fluid cytology preparations. 
Case 9
On October 15, a 43-year-old South Asian woman, also a
mail sorter at the US Postal Service facility in Hamilton but
at different mail sorting machines from those used by the
patient in Case 8, became ill. She had intermittent fevers
with chills, dry cough with chest discomfort and shortness of
breath, myalgias, and fatigue. She also had nausea and vom-
iting but no abdominal pain or diarrhea. She complained of
“head stuffiness” but no rhinorrhea or sore throat. She also
had headache and was reported to be mildly confused. On
October 16, when she visited her primary-care physician, she
had a temperature of 38oC and was started on levofloxacin
for bronchitis. Her past medical history was unremarkable,
and she did not smoke. On October 18, she went to a local
emergency room because of persistent symptoms.Vital signs
were as follows: temperature 38.4oC, heart rate 120/min, res-
piratory rate 16/min, and blood pressure 141/85mm Hg, with
oxygen saturation 92% on room air and 97% on 4 L of oxygen
by nasal cannula. She appeared ill and had decreased breath
sounds with egophony at the right base. WBC showed
increase in neutrophil band forms; hematocrit and platelet
count were normal. She had hyponatremia, but electrolytes,
renal function, and coagulation values were otherwise nor-
mal. Hepatic enzymes were elevated (Table 1). Blood PCR for
B. anthracis DNA obtained 2 days after initiation of antibiot-
ics was negative. A chest X-ray showed right hilar opacity
consistent with consolidation or mass, moderate right and
minimal left pleural effusions. Antibiotics were changed to
azithromycin and ciprofloxacin. Ciprofloxacin was discontin-
ued 24 hours later. On October 19, a chest CT showed
increased soft tissue in the mediastinum (thought to repre-
sent adenopathy), right hilar consolidation with possible
underlying mass, and large right pleural effusion. Clindamy-
cin and ceftriaxone were added, and thoracentesis was per-
formed with removal of 500 cc of serosanguinous fluid (Table
1). Pleural fluid cytology preparation was positive for  B.
anthracis cell-wall and capsule antigens by immunohis-
tochemical staining. On October 21, repeat thoracentesis
was required, and 800 cc of fluid was removed. On October
22, bronchoscopy found edematous, erythematous mucosa. A
transbronchial biopsy showed B. anthracis cell-wall and cap-
sule antigens by immunohistochemical staining. Cultures of
endobronchial samples, pleural fluid, and a nasal swab were
all negative for  B. anthracis, and no other pathogens were
identified. On October 23, the fever resolved, other symp-
toms began to improve, treatment was changed to doxycy-
cline, and the patient was discharged from the hospital on
doxycycline on October 26.
Case 10
On October 25, a 61-year-old Asian woman who worked
in the supply room of a New York City Hospital had onset of
malaise and myalgias. Over the next 2 days, she also had
fatigue, chills, chest pain, progressively worsening dyspnea,
and cough productive of sputum, which was later blood-
tinged; she denied fever. On October 28, 2001, when she
went to a local hospital (other than her workplace), she was
noted to be febrile in the emergency room and normotensive,
but her heart rate was 110/min and respiratory rate 38/min,
with room-air oxygen saturation of 92% by pulse oximetry.
She was awake, alert, and completely oriented. She had
prominent jugular venous distension at 60 degrees. She had
a history of hypertension. She did not smoke. Chest exami-
nation showed rales heard to the apices bilaterally. Abdomi-
nal and cardiovascular examinations were normal except for
tachycardia, and she had no peripheral edema. WBC count
was slightly elevated; hematocrit and platelets were normal.
Serum chemistries and coagulation studies were normal
except for hyponatremia, elevated hepatic enzymes, and
hypoalbuminemia. The serum lactate dehydrogenase level
was 1,370 IU/L. The patient required oxygen delivery by a
nonrebreather mask to maintain adequate oxygenation
(Table 1). Chest X-ray was initially interpreted as showingResearch
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pulmonary venous congestion with bilateral pleural effu-
sions. Therapy for congestive heart failure was initiated, but
an echocardiogram in the emergency department showed
normal ejection fraction, no substantial wall motion abnor-
malities, and a small pericardial effusion. Therapy was
changed to levofloxacin for atypical pneumonia. The
patient’s respiratory status worsened, and she was intu-
bated. A CT scan of the chest showed mediastinal lymphade-
nopathy, massive mediastinal bleeding, thickened bronchial
mucosa, and bilateral pleural effusions. Rifampin, gentami-
cin and subsequently nafcillin were added to her antimicro-
bial regimen. Early on October 29, 2001, bilateral chest
tubes were placed, and 2.5 liters of serosanguinous fluid was
drained from the right side and 1.0 liter from the left (Table
1). On the same day, bronchoscopy showed hemorrhagic
mucosa throughout the entire tracheobronchial tree, friable
and collapsible airways, and purulent secretions in multiple
segments bilaterally. On October 30, the antimicrobial regi-
men was changed to ciprofloxacin, rifampin, clindamycin,
and ceftazidime. Serial echocardiograms documented enlarg-
ing pericardial effusion, ultimately with tamponade. The
patient’s clinical condition progressively worsened, and she
died on October 31, after attempted pericardiocentesis. Cul-
tures of blood (after 20 hours) and pleural fluid grew  B.
anthracis. Autopsy findings included hemorrhagic medias-
tinitis; immunohistochemical stains confirmed the presence
of B. anthracis in multiple organs.
Clinical Summary
The median age of patients with inhalational anthrax in
this series was 56 years (range 43 to 73 years), 70% were
male and, except for the patient in Case 10, all were known
to or believed to have processed, handled, or received letters
containing  B. anthracis spores (postal workers [n=6], mail
handlers or sorters [n=2],  journalist [n=1]). The source of
exposure to B. anthracis spores in Case 10, a hospital supply
room worker, remains undefined. Four patients had underly-
ing cardiovascular or cerebrovascular disease, one had a
remote history of treated sarcoidosis and diet-controlled dia-
betes mellitus, and one had a history of asthma. None of the
patients was a current or recent smoker.
The median incubation period from the time of exposure
to onset of symptoms when known (n=6) was 4 days (range 4
to 6 days). Two of the patients (in Cases 8 and 9) are pre-
sumed to have been exposed on October 9, when a letter
later known to be contaminated with spores of B. anthracis
was processed in the postal facility where they worked. The
same letter was routed through a second postal facility and
processed on October 12, the presumed day of exposure for
four additional cases of inhalational anthrax (Cases 3, 4, 5,
and 6).
Patients sought care a median of 3.5 days (range 1 to 7
days) after onset of symptoms. Eight of 10 patients were in
the initial phase of illness when they first sought care. Of
these eight, six received antibiotics with activity against B.
anthracis on the same day, and all six survived. Four
patients, including one with meningitis, were exhibiting ful-
minant signs of illness when they first received antibiotics
with activity against B. anthracis, and all four died. Table 2
summarizes the symptoms of the 10 patients with bioterror-
ism-related anthrax. Table 3 lists major initial clinical, labo-
ratory and radiologic findings. The median initial WBC
count was 9,800/mm3 (range 7,500 to 13,300/mm3). However,
the median peak WBC count after presentation and during
the course of the illness was 26,400/mm3 (range 11,900 to
49,600/mm3). The chest X-ray was abnormal in all patients,
but only seven had mediastinal changes.
Pleural effusions were present in all 10 patients and
often became large during hospitalization in those who sur-
vived. Seven patients required drainage of pleural fluid,
three of these with chest tubes; pleural fluid was consis-
tently hemorrhagic with relatively few leukocytes. Pulmo-
nary infiltrates, which were seen in seven patients, involved
the right and left lower lobes (one patient), left upper and
lower lobes (one), right upper lobe (two), right lower lobe
(one), right middle and right lower lobes (one), and bilateral
Table 2. Symptoms for 10 patients with bioterrorism-related
inhalational anthrax, October-November 2001
Symptoms n=10
Fever, chills
Fatigue, malaise, lethargy
Cough (minimally or nonproductive) 
Nausea or vomiting
Dyspnea
Sweats, often drenching
Chest discomfort or pleuritic pain 
Myalgias
Headache
Confusion
Abdominal pain
Sore throat 
Rhinorrhea
10
10
9
9
8
7
7
6
5
4
3
2
1
Table 3. Initial clinical findings in 10 patients with bioterrorism-
related inhalational anthrax, October - November 2001
Physical findings
  Fever (>37.8o  C)
  Tachycardia (heart rate >100/min)
  Hypotension (systolic blood pressure <110
  mm Hg) 
7/10
8/10
1/10
Laboratory results
  White blood cell count (median, range)
     Differential – neutrophilia (>70%)
                          Neutrophil band forms (>5%)
  Elevated transaminases a
  (SGOT or SGPT > 40)
  Hypoxemia 
  (Alveolar-arterial oxygen gradient >30mm
  Hg on room air O2  saturation <94%)
  Metabolic acidosis 
  Elevated creatinine (>1.5 mg/dL)
9.8 x 103/mm3
7/10
4/5
9/10
6/10
2/10
1/10
Chest X-ray findings
  Any abnormality
  Mediastinal widening
  Infiltrates/consolidation
  Pleural effusion
10/10
7/10
7/10
8/10
Chest computed tomography findings
  Any abnormality
  Mediastinal lymphadenopathy, widening
  Pleural effusion 
  Infiltrates, consolidation
8/8
7/8
8/8
6/8
aSGOT = serum glutamic oxalacetic transaminase; SGPT = serum
glutamic pyruvic transaminaseResearch
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perihilar areas (one). Eight patients had a chest CT per-
formed; mediastinal lymphadenopathy was present in all but
one patient.
Blood cultures were obtained before antibiotic therapy
was initiated in seven patients, and  B. anthracis was iso-
lated in all seven. Blood cultures grew  B. anthracis at a
median of 18 hours (range 12 to 24 hours). Three patients
had the first set of blood cultures obtained after initiation of
antibiotic therapy; these cultures revealed no growth. One
patient with blood cultures that grew B. anthracis had blood
cultures repeated within 24 hours after initiating antibiotics
with activity against B. anthracis, and the repeat cultures
did not grow.
B. anthracis-specific immunohistochemical tests per-
formed on pleural fluid cytology preparations or transbron-
chial biopsy specimens were positive in every case in which
these tissues were available (three nonfatal cases) (Figure
7A). Three patients had atrial arrythmias (supraventricular
tachycardia in Case 2 and atrial fibrillation in Cases 5 and
7), and three patients had pericardial effusion on CT scan. In
one patient, pericardial tamponade was suspected. Six of 10
patients with inhalational anthrax have survived to date
(death rate 40%). Five have been discharged from the hospi-
tal, and one is recovering in the hospital. Figure 8 shows the
timeline from exposure (when known) to current status for
these 10 patients. Autopsy findings in all four patients who
died showed hemorrhagic mediastinal lymphadenitis and
evidence of disseminated B. anthracis infection (Figure7B-D)
Discussion
Before this outbreak of bioterrorism-related anthrax,
only 18 cases of inhalational anthrax had been reported in
the United States in the 20th century (1,4,9-21). The most
recent case was in 1976 (4). Most cases were related to expo-
sure to animal products, primarily in textile mills processing
goat hair, goat skins, or wool (1). Clinical characteristics in
the 10 cases due to bioterrorism described here share simi-
larities with previously reported cases but have important
differences.
Inhalational anthrax has been described as a biphasic
clinical illness characterized by a 1-to 4-day initial phase of
malaise, fatigue, fever, myalgias, and nonproductive cough,
followed by a fulminant phase of respiratory distress, cyano-
sis, and diaphoresis (1). Death follows the onset of the fulmi-
nant phase in 1 to 2 days (2,22). The symptoms of the initial
phase of inhalational anthrax in the 10 cases caused by bio-
terrorism (Table 1) were similar to those of the 18 occupa-
tionally related cases previously described (1); however, pro-
found, often drenching sweating, which was a prominent
feature in the current cases, was not emphasized in earlier
reports. Previous case reports have noted a brief period of
improvement between the initial and fulminant phases (1),
but this phenomenon was not observed in the current cases.
Nausea and vomiting were also frequent symptoms of the
initial phase in the current cases, suggesting early involve-
ment of the gastrointestinal tract. Gastrointestinal lesions
were observed in 39 of 42 total cases of fatal inhalational
anthrax associated with the Sverdlovsk outbreak (23). Most
lesions in these fatal cases appeared to represent hematoge-
nous spread of  B. anthracis to the submucosa of the gas-
trointestinal tract and did not involve Peyer’s patches or, in
most cases, mesenteric lymph nodes. The nondistinctive
nature of the initial phase of inhalational anthrax presents a
diagnostic challenge. The chest X-ray appeared to be a sensi-
tive indicator of disease in patients with bioterrorism-associ-
ated inhalational anthrax, as none of the 10 patients had an
initially normal chest X-ray. Multiple abnormalities were
noted on initial chest X-ray, including mediastinal widening,
paratracheal fullness, hilar fullness, pleural effusions,and
parynchemal infiltrates. Two patients had chest X-rays that
were interpreted initially as normal, but abnormalities
(mediastinal widening in one case and perihilar mass versus
Figure 7(A). Pleural fluid cell block from a nonfatal case showing abundant Bacillus anthracis granular antigen staining inside mononuclear
inflammatory cells. (Immunohistochemical assay with a mouse monoclonal anti-B. anthracis capsule antibody and detection with alkaline
phosphatase and naphthol fast red, original magnification 158X). (B) Mediastinal lymph node from a fatal case of anthrax showing extensive
capsular and sinusoidal hemorrhage. (Hematoxylin and eosin, original magnification 25X). (C) Lymph node from same case shown in B, show-
ing abundant B. anthracis granular antigen staining inside mononuclear inflammatory cells and bacilli (arrows) in the subcapsular hemor-
rhagic area. (Immunohistochemical assay with a mouse monoclonal anti-B. anthracis cell wall antibody and detection with alkaline
phosphatase and naphthol fast red, original magnification 100X). (D) Lung tissue from a fatal case showing  B. anthracis granular antigen
staining inside a perihilar macrophage (red arrow) and intra- and extracellular bacilli (black arrow). (Immunohistochemical assay with a
mouse monoclonal anti-B. anthracis cell wall antibody and detection with alkaline phosphatase and naphthol fast red, original magnification
100X)
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infiltrate in the other) were detected when the X-rays were
reviewed by a radiologist. Pulmonary infiltrates or effusion
were initially seen in two cases without evidence of mediasti-
nal widening. Chest CT was helpful in further characterizing
abnormalities in the lungs and mediastinum and was more
sensitive than chest X-ray in revealing mediastinal lym-
phadenopathy.
The total WBC count was usually normal or only
slightly elevated at the time of initial visit to a health-care
provider for patients who sought medical care in the initial
phase. However, an elevation in the proportion of neutro-
phils or band forms was frequently noted and was an early
diagnostic clue. During the course of illness, WBC counts
increased, sometimes markedly, in most patients. 
Blood cultures grew  B. anthracis even in the initial
phase of the illness in all patients who had not received prior
antibiotic therapy. Animal models suggest that primates
with inhalational anthrax become bacteremic early in the
course of the illness before the fulminant clinical phase
develops (24). In contrast, blood cultures rapidly became
sterile after initiation of antibiotic therapy, suggesting that
prior antibiotic treatment may substantially decrease the
sensitivity of blood cultures as a diagnostic test.
The diagnosis of anthrax was established in three
patients without growth of B. anthracis from clinical speci-
mens. In all three of these cases, proper cultures were
obtained only after initiation of antibiotic therapy. The diag-
nosis in these patients was established by a history of expo-
sure or occupational and environmental risk with a clinically
compatible syndrome, by the identification of B. anthracis in
pleural fluid, pleural biopsy, or transbronchial biopsy speci-
mens by immunohistochemical staining with  B. anthracis-
specific cell wall and capsular antibodies, or by identifying B.
anthracis DNA by PCR on pleural fluid or blood. Serologic
data from ELISA available for one patient with inhalational
anthrax also demonstrated a >4-fold increase in levels of
serum antibody (IgG) to the PA component of anthrax toxins.
The survival of patients with inhalational anthrax in
this series (60%) is higher than previously reported (<15%)
(1,3). All patients received combination antimicrobial ther-
apy with more than one agent active against B. anthracis.
The apparent improvement in survival compared with previ-
ous cases suggest that the antibiotic combinations used in
these patients may have therapeutic advantage over previ-
ous regimens. Limited data on treatment of the survivors
suggests that early treatment with a fluoroquinolone and at
least one other active drug (7) may improve survival. Other
antimicrobial susceptibilities of the isolates associated with
this outbreak have been published (7).  B. anthracis isolates
produce a cephalosporinase (7) that inhibits the antibacte-
rial activity of cephalosporins such as ceftriaxone, and ceph-
alosporins should not be used for treatment. Other
explanations for the improved survival rate include earlier
recognition and initiation of treatment, better supportive
care, differences in the pathogenesis of bioterrorism-related
anthrax, differences in susceptibility of the hosts, or a combi-
nation of the above.
Pleural effusions were a remarkably consistent clinical
feature of inhalational anthrax in this series, occurring in all
patients. The pleural effusions were often small on presenta-
tion, but in the surviving patients effusions were character-
ized by progressive enlargement and persistence. Drainage
of the pleural cavity was required in seven patients. The
characteristics of the pleural fluid in all patients were simi-
lar: hemorrhagic, with a high protein concentration and rela-
tively few WBCs. Immunohistochemistry demonstrated
large quantities of B. anthracis capsule and cell-wall anti-
gens in pleural tissue or pleural fluid cell blocks.
Figure 8. Timeline of 10 cases of inhalational anthrax in relation to onset of symptoms, October through November  2001. Research
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Case 2 was remarkable in that X-ray findings were dom-
inated by large and progressive pulmonary infiltrates, not by
mediastinal widening. In fact, no mediastinal adenopathy
was noted on chest CT. Transbronchial biopsies of the
patient in Case 2 showed B. anthracis-specific capsular and
cell-wall antigens in the lung parenchyma. Previous reports
have noted bronchopneumonia and pulmonary hemorrhagic
infarcts in patients with inhalational anthrax. Abramova et
al. (23) described focal hemorrhage and necrotizing anthrax
pneumonia in 11 of 42 patients who died with inhalational
anthrax. Characteristics of the spore-containing aerosol or
individual host factors may influence pathogenesis, so pul-
monary infiltrates may be a more prominent manifestation
in some patients with bioterrorism-related inhalational
anthrax. Three patients had supraventricular arrythmias,
and three had pericardial effusion on chest CT, one of which
may have progressed to tamponade. Pericardial effusions
may reflect toxin-related local edema or inflammation, hem-
orrhagic necrosis and infarct extending into the pericardium
from the mediastinum, or hematogenous spread of  B.
anthracis.
Anthrax meningitis is a complication of inhalational
anthrax and is characteristically hemorrhagic. Pathologic
findings are a hemorrhagic leptomeningitis with edema and
inflammatory infiltrates (2,23). Fifty-five percent of patients
at Sverdlovsk who died of inhalational anthrax had evidence
of meningeal involvement at autopsy. Cerebrospinal fluid
was examined in only two patients in our series, and menin-
gitis was documented in one. Three other patients had a his-
tory of intermittent confusion, but no meningeal signs were
observed, and lumbar punctures were not performed. No pre-
dominant underlying diseases or conditions were noted in
the patients with bioterrorism-related inhalational anthrax.
One patient (Case 5) had a remote history of sarcoidosis but
had been free of clinical illness or treatment associated with
this diagnosis for the past 25 years. One other case of inhala-
tional anthrax associated with underlying sarcoidosis has
been reported (12). The patient in Case 5 also had diabetes
mellitus, a condition present in one previously reported case
(12). Smoking did not appear to be a risk factor for inhala-
tional anthrax.
In summary, we describe the clinical presentation of the
first 10 cases of bioterrorism-related inhalational anthrax in
the United States. The clinical presentation in these patients
was variable and often resembled a viral respiratory illness,
but the interpretation of the initial symptoms in the context
of a possible exposure to B. anthracis often led to an early
diagnosis. In contrast to previous reports indicating a death
rate >85% (1,3), our series suggests that survival may be
markedly improved by combination antimicrobial therapy
begun during the initial phase of the illness and by aggres-
sive supportive care (e.g., drainage of pleural effusions).
Newer methods of detection such as polymerase chain reac-
tion, immunohistochemistry, and sensitive serologic tests are
important adjunctive diagnostic modalities that aid in the
diagnosis of  B. anthracis infections. Further studies are
needed to better define optimal antimicrobial regimens,
explore the role of adjunctive therapies (e.g., immunoglobu-
lin antitoxin, corticosteroids, and other toxin inhibitors), and
better understand the pathogenesis of inhalational anthrax
associated with intentional release.
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